ConductScience.org, home

Paper40908342

Neuronal ceroid lipofuscinosis: underlying mechanisms and emerging therapeutic targets.

Ziółkowska EA and 5 others. Nat Rev Neurol, 2025. Cited by 13 papers, by iCite.

Cite this record

ConductScience Library. Neuronal ceroid lipofuscinosis: underlying mechanisms and emerging therapeutic targets. Papers, record 40908342. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40908342

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Neuronal ceroid lipofuscinosis: underlying mechanisms and emerging therapeutic targets.
PubMed
Journal
Nat Rev Neurol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Research Support, N.I.H., Intramural, Review
PubMed
Citations, by iCite
13
iCite
Relative citation ratio, by iCite
3.82, provisional
iCite
Revised in PubMed
2026-08-13
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Neuronal Ceroid-LipofuscinosesMajor topic
Animals
Humans
Enzyme Replacement Therapy
Tripeptidyl-Peptidase 1

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R21 NS126907NINDS NIH HHSUnited StatesR21NS126907PubMedNIH RePORTER
R56 NS117635NINDS NIH HHSUnited StatesR56NS117635PubMedNIH RePORTER
R01 NS124655NINDS NIH HHSUnited StatesR01NS124655PubMedNIH RePORTER
R01 NS140682NINDS NIH HHSUnited StatesR01NS140682PubMedNIH RePORTER
R21 NS116574NINDS NIH HHSUnited StatesR21NS116574PubMedNIH RePORTER
RM1 NS132962NINDS NIH HHSUnited StatesRM1NS132962PubMedNIH RePORTER

Download CSV of grants

References219

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136078049Modelling Neurological Diseases in Large Animals: Criteria for Model Selection and Clinical Assessment.Cells2022https://conductscience.org/library/papers/36078049PubMed
219046998Sorting of lysosomal proteins.Biochim Biophys Acta2009https://conductscience.org/library/papers/19046998PubMed
322502604Mouse models of neuronal ceroid lipofuscinoses: useful pre-clinical tools to delineate disease pathophysiology and validate therapeutics.Brain Res Bull2012https://conductscience.org/library/papers/22502604PubMed
438211816Disruption of lysosomal nutrient sensing scaffold contributes to pathogenesis of a fatal neurodegenerative lysosomal storage disease.J Biol Chem2024https://conductscience.org/library/papers/38211816PubMed
54763201Infantile type of so-called neuronal ceroid-lipofuscinosis. Histological and electron microscopic studies.Acta Neuropathol1973https://conductscience.org/library/papers/4763201PubMed
640367194An AAV variant selected through NHP screens robustly transduces the brain and drives secreted protein expression in NHPs and mice.Sci Transl Med2025https://conductscience.org/library/papers/40367194PubMed
728506594Fingolimod and Teriflunomide Attenuate Neurodegeneration in Mouse Models of Neuronal Ceroid Lipofuscinosis.Mol Ther2017https://conductscience.org/library/papers/28506594PubMed
823297359Cathepsin F mutations cause Type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis.Hum Mol Genet2013https://conductscience.org/library/papers/23297359PubMed
911727201The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein.Am J Hum Genet2002https://conductscience.org/library/papers/11727201PubMed
1037305926A novel porcine model of CLN3 Batten disease recapitulates clinical phenotypes.Dis Model Mech2023https://conductscience.org/library/papers/37305926PubMed
1137113550Etiology of anxious and fearful behavior in juvenile neuronal ceroid lipofuscinosis (CLN3 disease).Front Psychiatry2023https://conductscience.org/library/papers/37113550PubMed
1230618709Association of GALC, ZNF184, IL1R2 and ELOVL7 With Parkinson's Disease in Southern Chinese.Front Aging Neurosci2018https://conductscience.org/library/papers/30618709PubMed
1338193346Proximity labelling reveals effects of disease-causing mutation on the DNAJC5/cysteine string protein α interactome.Biochem J2024https://conductscience.org/library/papers/38193346PubMed
1419556463A gene network regulating lysosomal biogenesis and function.Science2009https://conductscience.org/library/papers/19556463PubMed
1537942487Efficacy of dual intracerebroventricular and intravitreal CLN5 gene therapy in sheep prompts the first clinical trial to treat CLN5 Batten disease.Front Pharmacol2023https://conductscience.org/library/papers/37942487PubMed
1633543660Development of the "Hamburg Best Practice Guidelines for ICV-Enzyme Replacement therapy (ERT) in CLN2 Disease" Based on 6 Years Treatment Experience in 48 Patients.J Child Neurol2021https://conductscience.org/library/papers/33543660PubMed
1731807779Neonatal brain-directed gene therapy rescues a mouse model of neurodegenerative CLN6 Batten disease.Hum Mol Genet2019https://conductscience.org/library/papers/31807779PubMed
1832597833A CLN6-CLN8 complex recruits lysosomal enzymes at the ER for Golgi transfer.J Clin Invest2020https://conductscience.org/library/papers/32597833PubMed
1933930398Intravitreal gene therapy protects against retinal dysfunction and degeneration in sheep with CLN5 Batten disease.Exp Eye Res2021https://conductscience.org/library/papers/33930398PubMed
2035242840The Translational Benefits of Sheep as Large Animal Models of Human Neurological Disorders.Front Vet Sci2022https://conductscience.org/library/papers/35242840PubMed

See all 219 referencesDownload CSV of references

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.

PMIDTitleJournalYearIn PapersSource
42978612Case Report: A novel deep intronic MFSD8 splice-altering variant causes CLN7 disease through pseudoexon inclusion.Front Genet2026https://conductscience.org/library/papers/42978612PubMed
42883434Biofluid Proteomic Biomarker Discovery in a Large Animal Model of CLN2 Neuronal Ceroid Lipofuscinosis.Biology (Basel)2026https://conductscience.org/library/papers/42883434PubMed
42745943Autophagy-lysosomal pathway in neurodegeneration.Mol Neurodegener Adv2026https://conductscience.org/library/papers/42745943PubMed
42744859Batten disease protein CLN8 enables a non-canonical phospholipid synthesis pathway.Nat Cell Biol2026https://conductscience.org/library/papers/42744859PubMed
42490157Characterizing enteric pathology in MPS IIIA mice suggests disease-specific vulnerability among lysosomal storage disorders.JCI Insight2026https://conductscience.org/library/papers/42490157PubMed
42475369Chronic oral cannabidiol delays seizure onset and reduces seizure burden in a mouse model of CLN2 disease.PLoS One2026https://conductscience.org/library/papers/42475369PubMed
42377569A CLN8 biallelic missense variant causes epilepsy with severe treatment-resistant psychosis.Mol Genet Genomics2026https://conductscience.org/library/papers/42377569PubMed
42146456In vivo BMAL1 occupancy mapping using MACS-Calling Cards reveals disease-associated retargeting in Cln3 Δex7/8 astrocytes.bioRxiv2026https://conductscience.org/library/papers/42146456PubMed
42034784Antibiotic treatment reveals the contributions of the gut microbiome to CLN2 disease in the central and enteric nervous system.Sci Rep2026https://conductscience.org/library/papers/42034784PubMed
41977268Systemic AAV9 Gene Therapy Mitigates Neuromuscular Junction Degeneration and Muscle Atrophy in a Mouse Model of CLN1 Disease.Int J Mol Sci2026https://conductscience.org/library/papers/41977268PubMed
41890119Translational lipidomics reveals BMP and its precursor LPG as biomarkers for CLN5 Batten disease.bioRxiv2026https://conductscience.org/library/papers/41890119PubMed
41782446Transcriptomic and proteomic insights into progressive myoclonus epilepsy type 1.Dis Model Mech2026https://conductscience.org/library/papers/41782446PubMed
41466111Limited therapeutic efficacy of N-acetyl-L-leucine in a mouse model of CLN1 disease.Sci Rep2025https://conductscience.org/library/papers/41466111PubMed
41430350Enteric nervous system degeneration in human and murine CLN3 disease, is ameliorated by gene therapy in mice.Acta Neuropathol Commun2025https://conductscience.org/library/papers/41430350PubMed
41373441GAMT Deficiency: Clinical Presentation, Treatment, Diagnosis, Animal Models, Preclinical and Clinical Developments.Int J Mol Sci2025https://conductscience.org/library/papers/41373441PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40908342

GET https://conductscience.org/api/papers/v1/40908342/references?page=2